Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZNCF) Receivables - Other (2017 - 2024)

Historic Receivables - Other for Astrazeneca (AZNCF) over the last 6 years, with Q4 2024 value amounting to $1.6 billion.

  • Astrazeneca's Receivables - Other fell 366.08% to $1.6 billion in Q4 2024 from the same period last year, while for Dec 2024 it was $1.6 billion, marking a year-over-year decrease of 366.08%. This contributed to the annual value of $1.6 billion for FY2024, which is 366.08% down from last year.
  • Per Astrazeneca's latest filing, its Receivables - Other stood at $1.6 billion for Q4 2024, which was down 366.08% from $1.6 billion recorded in Q4 2023.
  • In the past 5 years, Astrazeneca's Receivables - Other registered a high of $1.8 billion during Q4 2021, and its lowest value of $1.6 billion during Q4 2024.
  • For the 4-year period, Astrazeneca's Receivables - Other averaged around $1.7 billion, with its median value being $1.6 billion (2022).
  • As far as peak fluctuations go, Astrazeneca's Receivables - Other crashed by 824.12% in 2022, and later crashed by 120.55% in 2023.
  • Quarter analysis of 4 years shows Astrazeneca's Receivables - Other stood at $1.8 billion in 2021, then fell by 8.24% to $1.7 billion in 2022, then dropped by 1.21% to $1.6 billion in 2023, then decreased by 3.66% to $1.6 billion in 2024.
  • Its Receivables - Other was $1.6 billion in Q4 2024, compared to $1.6 billion in Q4 2023 and $1.7 billion in Q4 2022.